What is Proveca?
Proveca Ltd is a specialized pharmaceutical firm headquartered in Manchester, United Kingdom, dedicated to developing and providing medicines tailored for children. This focus positions the company within a critical but often underserved segment of the healthcare market, requiring specialized research, development, and regulatory expertise to address the unique physiological needs of pediatric patients. The company's commitment to this niche underscores its strategic importance in advancing pediatric healthcare solutions.
How much funding has Proveca raised?
Proveca has raised a total of $9.2M across 2 funding rounds:
Private Equity
$4.2M
Private Equity
$5M
Private Equity (2013): $4.2M with participation from Albion Ventures
Private Equity (2017): $5M led by Catapult Ventures, GM&C Life Sciences Fund, and Kreos Capital
Key Investors in Proveca
Albion Ventures
AlbionVC is the technology investment arm of Albion Capital Group LLP, managing approximately £1 billion in venture funds and supporting visionary founders with long-term capital and scale-up expertise. The firm primarily invests in high-growth B2B software and technology-enabled services companies, focusing on early-stage investments from seed to Series B, predominantly in the UK.
Catapult Ventures
Catapult Ventures specializes in providing tailored investment solutions to meet the funding needs of entrepreneurs and business owners. The company focuses on unlocking potential and supporting clients in realizing their goals and ambitions. With years of experience and a successful track record, Catapult Ventures positions itself as a reliable investment partner.
Kreos Capital
Kreos Capital Group Ltd is a company that specializes in finance. It provides investment services and business management. The company was formed in 1998 and is headquartered in London, United Kingdom.
What's next for Proveca?
The substantial enterprise-level backing and recent strategic investment indicate Proveca is poised for significant scaling and expansion. This capital infusion is likely earmarked for accelerating drug development pipelines, expanding clinical trials, enhancing manufacturing capabilities, and potentially pursuing market approvals and commercialization efforts. The company's trajectory suggests a move towards solidifying its market presence and broadening its portfolio of pediatric therapeutics, aiming to address unmet medical needs in child healthcare.
See full Proveca company page
